Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Early triple-negative breast cancer patients who received pembrolizumab along with neoadjuvant chemotherapy had a significantly higher rate of pathological complete responses than those who received placebo along with neoadjuvant chemotherapy.
Oncology, Medical November 28th 2022
The median PFS and overall survival in the hormone receptor-positive cohort (494; 88.7%) were 23.9 months and 17.5 months, respectively, for the trastuzumab deruxtecan group and 10.1 months and 5.4 months, respectively, for the physician’s choice group. Overall survival was 23.4 months and 16.8 months, respectively, while the median PFS for all patients was 9.9 months for the trastuzumab deruxtecan group and 5.1 months for the physician’s choice group.
Oncology, Medical November 14th 2022
Neoadjuvant nivolumab plus chemotherapy improved event-free survival and increased the proportion of patients who had a pathological complete response in patients with resectable NSCLC compared to chemotherapy alone. Nivolumab was added to neoadjuvant chemotherapy, but neither the incidence of side effects nor the viability of surgery was affected.
Oncology, Medical November 7th 2022
Journal of Clinical Oncology
The researchers believe these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, demonstrating comparable efficacy and manageable safety. Experimentation revealed that FGFR3 DNA alterations in conjunction with FGFR1/3 mRNA overexpression may be better predictors of rogaratinib response.
Hematology October 24th 2022
Blood Advances
Even with superior frontline therapy using A+CHP, this exploratory study suggests that consolidative SCT should be considered in CD30+ peripheral T-cell lymphoma (PTCL) patients. More large-scale studies are needed, especially in DUSP22-rearranged and low International Prognostic Index ALK ALCL, to determine whether there are favorable subgroups that could be treated with A+CHP alone.
First-line pembrolizumab and pembrolizumab-chemotherapy continued to outperform cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after a 4-year follow-up. Following pembrolizumab-based therapy, patients responded well to subsequent treatment.
Oncology, Medical October 19th 2022